1, Changshan pharmaceutical: in the first quarter of 202 1, the company's total revenue was 7 1 1 billion, gross profit margin was 6 1. 19%, and earnings per share was 0.0700 yuan. The main heparin products are heparin sodium bulk drug, heparin sodium injection, enoxaparin sodium bulk drug, damartin sodium bulk drug, low molecular weight heparin calcium bulk drug, damartin sodium injection and low molecular weight heparin calcium injection.
2. Shuanglu Pharmaceutical: In the first quarter of 2002/KLOC-0, the total revenue of the company was 253 million, the gross profit margin was 87.69%, and the earnings per share was 0.0900 yuan. The company's genetic engineering products, temozolomide, Ling Xing dropping pills, enoxaparin sodium, etc. Thanks to the promotion of bidding, the sales increased by more than 40%.
3. Hong Qian Pharmaceutical: In the first quarter of 200210, the company's total revenue was 39 1 100 million, with a gross profit margin of 44.56% and earnings per share of 0.0400 yuan. The company's quality control level of heparin sodium raw materials has reached the international advanced level, and passed the COS certification of the European Union and GMP certification of Germany, Australia, Brazil and South Korea. The heparin product produced by the company as the raw material of enoxaparin has passed the on-site inspection of FDA, and the raw material of heparin sodium is now applying for the certification of FDA. The raw material "heparin sodium" has obtained the import license from the Japanese Ministry of Health and Welfare on March 20 10, and the raw materials and preparations of pancreatic kininogenase of the company have been imported.
4. Shanghai: 202 1 1 quarter, the company's total revenue12.68 million, gross profit margin of 32.97%, earnings per share of 0.0978 yuan. The core technology used in the company's production-heparin sodium extraction and purification technology, including impurity and component separation technology, virus and bacteria inactivation technology, group integrity protection and activity release technology, component directional separation technology.
5. Jianyou shares: In the second quarter of 2002/KLOC-0, the company achieved total revenue of 868 million, gross profit margin of 57.37% and earnings per share of 0.3000 yuan. In terms of heparin preparation, the company's main low molecular weight heparin preparations including enoxaparin sodium injection, daparine sodium injection and nadroparin calcium injection have been approved by CFDA.
The stock market is risky, so you need to be cautious in investing.